NEW YORK, June 29 – Illumina will provide SNP genotyping services on a set of samples provided by GlaxoSmithKline, the companies said Friday.
The agreement calls for Illumina to apply its BeadArray technology to determine the frequency of specific SNPs in the GlaxoSmithKline samples. The companies did not disclose further details.
Illumina’s SNP scoring technology is based on a technique, developed together with Applied Biosystems, for attaching strands of DNA to beads, which are then placed in an indentation on the tip of a fiber optic bundle. The company arrays these bundles onto a cassette that matches up with a standard 96-well microtiter plate.
Chevron has also commissioned Illumina to study how the BeadArray technology could be applied to detecting certain compounds in hydrocarbon processing operations.